PF-562271 HCl: Applied FAK/Pyk2 Inhibition in Cancer Research

Principle Overview: Harnessing PF-562271 HCl for Tumor Biology

PF-562271 HCl is a potent, ATP-competitive, and reversible inhibitor targeting focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), two critical mediators of cell adhesion, migration, proliferation, and survival. With an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, this compound enables selective interrogation of FAK/Pyk2-driven pathways in cancer models (source: product_spec). Its high selectivity and well-characterized mechanism make it a cornerstone for studies dissecting tumor growth inhibition, metastasis, and tumor microenvironment modulation.

The continued emergence of resistance to targeted therapies in cancers such as HER2-positive breast cancer underscores the need for orthogonal approaches—such as FAK/Pyk2 inhibition—to probe alternative signaling axes and identify new therapeutic strategies (source: Keller et al., 2023). APExBIO’s PF-562271 HCl stands out for its batch-to-batch consistency and comprehensive documentation, streamlining assay design and data interpretation.

Step-by-Step Workflow: Protocol Enhancements for Reliable Data

Optimal results with PF-562271 HCl depend on tailored protocol parameters and rigorous handling. Below is a consolidated, evidence-based workflow to maximize the reliability and interpretability of FAK/Pyk2 inhibition experiments:

Protocol Parameters

• cell culture assay | 0.1–10 μM (final concentration) | In vitro FAK/Pyk2 inhibition in cancer cell lines | Covers the reported EC₅₀ and IC₅₀ range, enabling dose-response and mechanistic studies | product_spec, workflow_recommendation
• solvent preparation | ≥26.35 mg/mL in DMSO (gentle warming) | Stock solution preparation for screening and mechanistic assays | Ensures complete solubilization; avoid water or ethanol due to insolubility | product_spec
• incubation time | 1–24 hours | Acute and sustained pathway inhibition | Captures both immediate and adaptive cellular responses; pilot time-course studies recommended for each cell type | workflow_recommendation
• storage condition | -20°C, desiccated, protected from light | Long-term compound stability | Preserves activity and prevents degradation for reproducible results | product_spec
• in vivo dosing | 16.7–33.3 mg/kg daily (mouse xenograft) | Tumor growth/metastasis models | Reflects doses used for effective FAK phosphorylation inhibition and tumor suppression | product_spec, workflow_recommendation

Key Innovation from the Reference Study

The study by Keller et al. (2023) demonstrated that targeting metabolic enzymes linked to cell adhesion and migration, such as EDI3, can sensitize HER2-positive breast cancer cells resistant to conventional therapies (source: Keller et al., 2023). Their approach combined genetic silencing with pharmacological inhibition to reduce tumor viability and growth both in vitro and in vivo. Translationally, this reinforces the value of using selective kinase inhibitors like PF-562271 HCl to dissect the interplay between focal adhesion signaling and metabolic vulnerabilities. For researchers, this means incorporating FAK/Pyk2 inhibition alongside metabolic pathway modulation can reveal synergistic or compensatory mechanisms that drive tumor persistence and adaptation.

Advanced Applications and Comparative Advantages

PF-562271 HCl’s high selectivity for FAK and Pyk2, with over 100-fold selectivity against most other kinases except some CDKs, positions it as a gold-standard tool for targeted pathway inhibition (source: product_spec). In xenograft models, it demonstrated dose-dependent suppression of FAK phosphorylation (EC₅₀ = 93 ng/mL) and robust inhibition of tumor proliferation and metastasis (source: product_spec). This makes it ideal for:

• Mechanistic dissection: Clarifying the role of FAK/Pyk2 in cytoskeletal remodeling, adhesion, and migration.
• Resistance modeling: Exploring how tumors adapt to FAK/Pyk2 inhibition, informing combination strategies with metabolic or immune modulators.
• Tumor microenvironment studies: Examining the impact on stromal cell signaling, angiogenesis, and immune infiltration.

Comparative reviews—such as the article "PF-562271 HCl: Applied Workflows for FAK/Pyk2 Inhibition in Cancer Research" (ponesimodbuy.com)—extend these insights by providing stepwise protocols and troubleshooting FAQs, complementing this guide with scenario-driven adaptations to diverse cancer models.

Meanwhile, "PF-562271 HCl: A Selective FAK/Pyk2 Inhibitor for Advance..." (itf2357.com) contrasts the efficacy of PF-562271 HCl against other FAK inhibitors, highlighting its ATP-competitive, reversible profile as a differentiator for studies requiring pathway reversibility and kinetic resolution.

Troubleshooting & Optimization Tips

Solubility and Handling: PF-562271 HCl is highly soluble in DMSO at ≥26.35 mg/mL with gentle warming, but insoluble in water or ethanol. Incomplete dissolution can result in variable dosing—always verify clarity of stock solutions and avoid repeated freeze-thaw cycles (source: product_spec).

Assay Design: The observed magnitude of FAK phosphorylation inhibition may vary based on cell density, serum conditions, and baseline pathway activity. Pilot experiments to titrate both compound and stimulus (e.g., integrin agonists or growth factors) are recommended (source: workflow_recommendation).

Data Interpretation: Given PF-562271 HCl’s partial activity against some CDKs, include appropriate kinase selectivity controls and, where feasible, orthogonal readouts (e.g., phospho-specific Western blots, cell migration assays) to confirm target engagement (source: cdk2-cyclin-inhibitory-peptide-i.com).

Batch Consistency: Always document lot numbers and supplier; APExBIO’s rigorous QC process ensures reproducibility, but inter-vendor variability is a known pitfall (source: workflow_recommendation).

Future Outlook: Integrating FAK/Pyk2 Inhibition with Cancer Systems Biology

As cancer research evolves, precision tools like PF-562271 HCl will continue to illuminate the multifaceted roles of focal adhesion kinase signaling in tumor adaptation, immune evasion, and microenvironmental crosstalk. Evidence from metabolic targeting studies (such as Keller et al., 2023) supports the rationale for combining FAK/Pyk2 inhibition with interventions that disrupt metabolic or immune pathways, especially in therapy-resistant models (source: Keller et al., 2023). The ability to reversibly and selectively inhibit FAK/Pyk2 at nanomolar concentrations empowers researchers to map adaptive signaling networks and identify actionable vulnerabilities with high temporal and mechanistic resolution.

Looking forward, application of standardized, data-driven protocols—supported by trusted suppliers like APExBIO—will be central to translating bench discoveries into robust, preclinical evidence for next-generation cancer therapeutics.

For full product details and batch-specific documentation, visit the PF-562271 HCl page at APExBIO.